In the Margins

Sequoia's Valeant bet hard lesson for investors

March 29, 2016

By MarketWatch

Sequoia Fund investors learned a hard lesson when the fund's investment in Valeant Pharmaceuticals went bad last year. "Bad doesn’t even begin to describe the situation for Sequoia, one of the most legendary mutual funds, which has seen its reputation torched by a bad bet on a controversial stock," writes MarketWatch's Chuck Jaffe in his latest column. Robert Goldfarb, CEO of adviser Ruane, Cunniff & Goldfarb and co-manager of Sequoia, resigned his fund duties last Wednesday. Read the original column from MarketWatch

 

 

Most Read

Top of the Agenda - Compensation
IDC director study: 2019 pay relatively unchanged

New data from Independent Directors Council suggests that most independent mutual fund directors did not see much of a bump in compensation in 2019, with year-on-year ...